{"id":452205,"date":"2021-03-08T02:03:09","date_gmt":"2021-03-08T07:03:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=452205"},"modified":"2021-03-08T02:03:09","modified_gmt":"2021-03-08T07:03:09","slug":"oxurion-to-participate-in-upcoming-investor-meetings","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oxurion-to-participate-in-upcoming-investor-meetings\/","title":{"rendered":"OXURION to Participate in Upcoming Investor Meetings"},"content":{"rendered":"
\n

\n Leuven, BE, Boston, MA, US \u2013 March 8, 2021 \u2013 08.00 AM CET <\/strong>\u2013 Oxurion NV<\/a> (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical stage portfolio in diabetic eye disease, today announces its management will participate and meet with investors at the following upcoming\u00a0virtual\u00a0meetings in March:\u00a0
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
\u00a0\u00a0\u00a0\u00a0\u00b7\u00a0H.C. Wainwright Global Life Sciences Conference – March 9-10, 2021<\/em><\/strong>
\u00a0Pre-Recorded Company Presentation<\/em>, featuring Tom Graney, CFA, CFO<\/em><\/strong> to be made live on March 9 at 7:00 am EST.
The presentation will be available in the events section of Oxurion\u2019s website at www.oxurion.com.
A replay will be available for approximately 90 days following the conference.<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00b714th Annual European Life Sciences CEO Forum – March 10-11, 2021<\/em><\/strong>
Pre-Recorded Company Presentation<\/em>, featuring Patrik De Haes, MD, CEO<\/em><\/strong> available on demand for all registered users to view on events portal.<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00b733rd Annual Roth Conference – March 15-17, 2021<\/em><\/strong>
Oxurion to join panel discussion<\/em> entitled \u2018Disruptive Back of the Eye Therapies<\/em>\u2019 which will take place on March 16 at 9:00 am EST.<\/p>\n

\n END<\/strong>\n <\/p>\n

\n For further information please contact:<\/strong>\n <\/p>\n\n\n
\n Oxurion NV<\/u>
\n
Wouter Piepers,
Global Head of Investor Relations
& Corporate Communications
Tel: +32 16 75 13 10 \/ +32 478 33 56 32
wouter.piepers@oxurion.com<\/a><\/p>\n

<\/td>\n

\n EU <\/u>
\n
\n Citigate Dewe Rogerson <\/u>
\n
David Dible\/ Sylvie Berrebi\/Frazer Hall
Tel: +44 20 7638 9571
oxurion@citigatedewerogerson.com<\/a><\/p>\n

\u00a0<\/p>\n

US<\/u>
Westwicke, an ICR Company<\/u>
Christopher Brinzey
Tel: +1 617 835 9304
chris.brinzey@westwicke.com<\/a><\/td>\n<\/tr>\n<\/table>\n

\n About Oxurion <\/strong>\n <\/p>\n

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide. <\/p>\n

Oxurion is aiming to build the leading global franchise in the treatment of DME, based on the successful development of its two novel therapeutics:<\/p>\n